A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents With Type 3 Gaucher Disease
Phase of Trial: Phase I/II
Latest Information Update: 12 Apr 2016
Price : $35 *
At a glance
- Drugs Velaglucerase alfa (Primary)
- Indications Gaucher's disease type III
- Focus Therapeutic Use
- Sponsors Shire
- 20 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 27 Apr 2014 Planned End Date changed from 1 Aug 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.